Z

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357

Watchlist Manager
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Watchlist
Price: 24.11 CNY -3.13% Market Closed
Market Cap: 12.6B CNY
Have any thoughts about
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd?
Write Note

Income Statement

Earnings Waterfall
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

Revenue
891.2m CNY
Cost of Revenue
-49.5m CNY
Gross Profit
841.7m CNY
Operating Expenses
-515m CNY
Operating Income
326.7m CNY
Other Expenses
-15.8m CNY
Net Income
310.8m CNY

Income Statement
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024
Revenue
Revenue
211
N/A
228
+8%
240
+5%
247
+3%
252
+2%
261
+3%
267
+2%
277
+4%
283
+2%
303
+7%
312
+3%
324
+4%
344
+6%
367
+7%
386
+5%
411
+7%
439
+7%
478
+9%
501
+5%
532
+6%
557
+5%
615
+11%
639
+4%
612
-4%
625
+2%
631
+1%
636
+1%
691
+9%
724
+5%
765
+6%
808
+6%
841
+4%
849
+1%
888
+5%
896
+1%
882
-2%
893
+1%
870
-3%
848
-2%
881
+4%
891
+1%
Gross Profit
Cost of Revenue
(11)
(11)
(10)
(12)
(13)
(13)
(13)
(15)
(14)
(14)
(12)
(12)
(12)
(13)
(14)
(22)
(25)
(32)
(29)
(29)
(27)
(26)
(23)
(26)
(31)
(31)
(29)
(34)
(33)
(35)
(34)
(40)
(40)
(44)
(41)
(47)
(49)
(46)
(40)
(47)
(49)
Gross Profit
201
N/A
217
+8%
230
+6%
235
+2%
239
+2%
247
+3%
254
+3%
263
+3%
269
+2%
290
+8%
301
+4%
312
+4%
331
+6%
355
+7%
372
+5%
390
+5%
414
+6%
446
+8%
472
+6%
503
+6%
529
+5%
589
+11%
617
+5%
586
-5%
594
+1%
600
+1%
608
+1%
657
+8%
691
+5%
730
+6%
773
+6%
801
+4%
809
+1%
844
+4%
855
+1%
834
-2%
844
+1%
823
-2%
808
-2%
834
+3%
842
+1%
Operating Income
Operating Expenses
(116)
(121)
(123)
(116)
(118)
(121)
(127)
(131)
(136)
(141)
(152)
(153)
(156)
(161)
(167)
(170)
(182)
(198)
(220)
(237)
(254)
(281)
(300)
(299)
(304)
(312)
(314)
(328)
(353)
(372)
(409)
(413)
(406)
(423)
(485)
(495)
(522)
(529)
(494)
(506)
(515)
Selling, General & Administrative
(114)
(120)
(112)
(115)
(117)
(120)
(116)
(129)
(135)
(140)
(142)
(151)
(155)
(158)
(159)
(168)
(178)
(193)
(204)
(223)
(232)
(253)
(257)
(253)
(253)
(253)
(260)
(279)
(299)
(317)
(330)
(341)
(341)
(357)
(355)
(365)
(379)
(380)
(373)
(401)
(410)
Research & Development
0
0
(11)
0
0
0
(10)
0
0
0
(9)
0
0
(2)
(8)
0
0
(3)
(11)
(14)
(22)
(31)
(35)
(46)
(52)
(60)
(56)
(74)
(79)
(81)
(75)
(95)
(98)
(103)
(92)
(104)
(107)
(108)
(96)
(118)
(122)
Depreciation & Amortization
0
0
(0)
0
0
0
(1)
0
0
0
(1)
0
0
0
(1)
0
0
0
(4)
0
0
0
(7)
0
0
0
(12)
0
0
0
(22)
0
0
0
(24)
0
0
0
(33)
0
0
Other Operating Expenses
(2)
(1)
(0)
(1)
(1)
(1)
(0)
(2)
(1)
(1)
(0)
(2)
(1)
(1)
1
(0)
(2)
(2)
(0)
(0)
0
3
0
0
0
0
15
25
26
26
18
22
33
37
(14)
(27)
(37)
(41)
8
14
17
Operating Income
85
N/A
97
+14%
107
+10%
119
+12%
121
+2%
126
+4%
127
+1%
132
+4%
133
+1%
148
+12%
148
0%
160
+8%
176
+10%
194
+10%
205
+6%
220
+7%
232
+6%
248
+7%
252
+2%
266
+5%
275
+3%
308
+12%
317
+3%
287
-9%
289
+1%
288
-1%
294
+2%
328
+12%
339
+3%
357
+6%
364
+2%
388
+6%
403
+4%
421
+5%
369
-12%
339
-8%
322
-5%
294
-9%
314
+7%
328
+4%
327
0%
Pre-Tax Income
Interest Income Expense
2
3
6
7
8
8
7
7
7
7
8
8
9
10
12
13
15
17
19
22
24
26
27
26
26
28
27
28
29
27
29
30
30
30
27
27
27
26
31
30
31
Non-Reccuring Items
0
0
0
0
0
0
0
0
0
0
(5)
(5)
(5)
(5)
(0)
(0)
(0)
(0)
(0)
0
0
0
0
0
0
0
0
0
0
0
(0)
(0)
(0)
(0)
(0)
0
0
0
(0)
0
0
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
0
0
0
(4)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
5
5
7
6
5
5
5
5
2
2
0
1
1
5
3
2
1
2
2
1
3
4
2
4
3
9
1
(0)
1
(7)
0
1
(0)
0
3
2
2
1
1
1
(2)
Pre-Tax Income
92
N/A
105
+13%
119
+14%
132
+11%
134
+2%
139
+4%
139
0%
143
+3%
142
-1%
154
+8%
152
-1%
164
+8%
181
+11%
205
+13%
219
+7%
235
+7%
248
+6%
266
+7%
273
+3%
289
+6%
302
+5%
337
+12%
346
+2%
317
-8%
318
+0%
325
+2%
323
-1%
356
+10%
368
+4%
378
+2%
393
+4%
418
+6%
432
+3%
451
+4%
399
-11%
367
-8%
351
-5%
322
-8%
346
+8%
359
+4%
356
-1%
Net Income
Tax Provision
(14)
(15)
(19)
(22)
(23)
(23)
(21)
(21)
(21)
(25)
(23)
(25)
(27)
(29)
(33)
(35)
(37)
(40)
(41)
(44)
(46)
(52)
(53)
(49)
(50)
(52)
(53)
(58)
(61)
(65)
(67)
(71)
(72)
(72)
(63)
(54)
(49)
(45)
(50)
(57)
(59)
Income from Continuing Operations
78
90
100
110
112
116
118
122
121
129
129
139
154
175
186
200
211
227
232
245
257
286
293
267
268
273
270
297
308
313
326
348
360
379
336
314
301
277
296
302
296
Income to Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
3
5
6
6
7
8
9
10
11
11
12
12
11
12
13
14
15
15
15
14
14
Net Income (Common)
78
N/A
90
+14%
100
+11%
111
+11%
112
+1%
116
+4%
118
+2%
122
+4%
121
-1%
129
+7%
129
N/A
139
+8%
154
+11%
175
+14%
186
+6%
200
+7%
211
+6%
227
+7%
233
+3%
247
+6%
259
+5%
290
+12%
298
+3%
274
-8%
275
+1%
281
+2%
278
-1%
308
+10%
319
+4%
324
+2%
338
+4%
359
+6%
372
+3%
391
+5%
349
-11%
328
-6%
316
-3%
292
-8%
310
+6%
317
+2%
311
-2%
EPS (Diluted)
0.2
N/A
0.17
-15%
0.19
+12%
0.21
+11%
0.22
+5%
0.23
+5%
0.23
N/A
0.23
N/A
0.23
N/A
0.24
+4%
0.25
+4%
0.26
+4%
0.29
+12%
0.33
+14%
0.36
+9%
0.38
+6%
0.4
+5%
0.43
+7%
0.44
+2%
0.47
+7%
0.49
+4%
0.55
+12%
0.57
+4%
0.52
-9%
0.53
+2%
0.54
+2%
0.53
-2%
0.58
+9%
0.6
+3%
0.61
+2%
0.65
+7%
0.69
+6%
0.71
+3%
0.75
+6%
0.67
-11%
0.63
-6%
0.6
-5%
0.56
-7%
0.59
+5%
0.61
+3%
0.59
-3%

See Also

Discover More